Epub: Ghezzi et al. Nataluzimab in pediatric multiple sclerosis: results of a cohort of 55 cases. Mult Scler. 2013 Feb 11.
OBJECTIVE: The purpose of this study was to describe the long-term effects of NA in a large cohort of active ped-MSers.
METHODS: Ped-MSers were treated with NA if in the previous year they had experienced at least two relapses or a severe relapse with incomplete recovery while on immunomodulating treatment, or at least two relapses and new magnetic resonance imaging (MRI) lesions regardless of any prior treatment.
RESULTS: The study included 55 ped-MSers (mean age: 14.4 years, mean number of relapses: 4.4, pre-treatment mean disease duration: 25.5 months). They received a median number of 26 infusions. Three relapses occurred during the follow-up, one female ped-MSer continued to deteriorate in cognitive functioning. Mean Expanded Disability Status Scale (EDSS) scores decreased from 2.7 to 1.9 at the last visit (p<0.001). During the follow-up the majority of ped-MSers remained free from MRI activity. Transient and mild clinical adverse events occurred in 20 ped-MSers . Mild hematological abnormalities occurred in seven ped-MSers. Anti-JCV antibodies were detected in 20/51 tested ped-MSers.
CONCLUSIONS: NA was well tolerated in all ped-MSers. A strong suppression of disease activity was observed in the majority of ped-MSers during the follow-up.